J. K. Rowling's Donation for Multiple-Sclerosis Research

Facebook ↗WhatsApp ↗

First published March 12, 2020.

The grant and the work it funds

The amount belongs to a dated commitment. Research outputs and patient benefits develop separately and should not be assumed from the donation figure alone.

J. K. Rowling's Donation for Multiple-Sclerosis Research

You might recognize her as the author of the Harry Potter book series, but JK Rowling is also a philanthropist.


The author was reported to have donated a large sum to fund multiple sclerosis (MS) research, the same debilitating condition that took her mother.


In total, the author and philanthropist donated a whopping £15.3 million ($18.8 million) to the University of Edinburgh.


With the funds, they can further development of the Anne Rowling Regenerative Neurology Clinic.


According to GoodNewsNetwork, the clinic was built in 2010 following a mighty donation from Rowling.


She named the section after her mom, Anne, who died from multiple sclerosis at the age of 45.


Apart from furthering neurodegenerative treatments and cures, the funds will be used to finance the construction of facilities of the clinic.


The donation will also be used to explore how healthcare workers can improve the lives of patients who suffer from similarly debilitating diseases.

When the gift was made and what it funds

The University of Edinburgh announced the £15.3 million gift (the figure includes Gift Aid) on 12 September 2019, six months before this article appeared. It funds new facilities and research at the Anne Rowling Regenerative Neurology Clinic, including work on the less visible symptoms of MS such as cognitive problems and pain. The clinic itself was set up after an earlier donation from Rowling in 2010. Anne Rowling died of MS at the age of 45.

Sources: University of Edinburgh, Centre for Clinical Brain Sciences, 12 September 2019

The donation and its results have different timelines

Rowling’s research donation is a funding commitment rather than an immediate treatment outcome. Buildings, clinical work and research programmes develop through different stages, so the amount alone cannot show what patients later benefited from. The clinic’s own dated reporting is the appropriate place to trace those developments.

COMMENTS